Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic Review
Open accessThe DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognosis, specifically the case fatality and duration, of untreated tuberculosis is important as many patients are not correctly diagnosed and therefore receive inadequate or no treatment. Furthermore, duration and case fatality of tuberculosis are key parameters in interpreting epidemiological data. METHODOLOGY AND PRINCIPAL FINDINGS: To estimate the duration and case fatality of untreated pulmonary tuberculosis in HIV negative patients we reviewed studies from the pre-chemotherapy era. Untreated smear-positive tuberculosis among HIV negative individuals has a 10-year case fatality variously reported between 53% and 86%, with a weighted mean of 70%. Ten-year case fatality of culture-positive smear-negative tuberculosis was nowhere reported directly but can be indirectly estimated to be approximately 20%. The duration of tuberculosis from onset to cure or death is approximately 3 years and appears to be similar for smear-positive and smear-negative tuberculosis. CONCLUSIONS: Current models of untreated tuberculosis that assume a total duration of 2 years until self-cure or death underestimate the duration of disease by about one year, but their case fatality estimates of 70% for smear-positive and 20% for culture-positive smear-negative tuberculosis appear to be satisfactory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Selection of papers. Flowchart schematically showing inclusion and exclusion of papers. Those marked with a * were excluded either because they were referred to at places in the text that did not discuss duration of tuberculosis, tuberculosis mortality, case fatality, life tables or natural history, or because the title indicated that the paper was not about one of these topics; ** for two of these, data were included to the extent mentioned by Berg [115] (see legend of Table 3).](https://figures.cochat.ai/paper-figures/8114c3bf70fd484d9fe91b2b4854751c/natural-history-of-tuberculosis-duration-and-fatality-of-untreated-pulmonary-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the average duration until cure or death is 3 years for untreated patients with tuberculosis,25”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553 · cited 2×
“a 70% CF, as used by WHO and others in their estimates of the burden of tuberculosis [27], seems a reasonable ballpark figure.”
BackgroundMethodSelf-citationTuberculosis and diabetes mellitus: convergence of two epidemics
Dooley, K. E., & Chaisson, R. E. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70282-8 · Cited by 932 · cited 1×
“tuberculosis and progression to tuberculosis disease is influenced by host factors and especially risk of progression depends on the hosts’ immune status, which may be reduced due to concomitant HIV infection, diabetes, and other underlying diseases [27,28].”
BackgroundFluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review
Steingart, K. R., Henry, M., Ng, V., Hopewell, P. C., Ramsay, A., Cunningham, J., Urbanczik, R., Perkins, M., Aziz, M. A., & Pai, M. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70578-3 · Cited by 798 · cited 1×
“smear, with low sensitivity for paucibacillary disease, is the only available diagnostic tool [6].”
BackgroundThe Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627 · cited 1×
“Furthermore, Mycobacterium tuberculosis strains resistant to rifampicin and INH might be less fit than drug susceptible strains and therefore lead to longer duration of disease with less mortality [15].”
BackgroundDye, C. (2005) · JAMA · doi:10.1001/jama.293.22.2767 · Cited by 534 · cited 1×
“course) strategy only offer free treatment to smear-positive cases in view of their disproportionate role in tuberculosis transmission and thus their large public health impact [7].”
BackgroundEspinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507 · cited 1×
“The prognosis of untreated tuberculosis is difficult to study these days as leaving patients untreated, especially in a study setting, is unethical. As an alternative, one could consider, as an approximation, the prognosis of multi-drug resistant (MDR) tuberculosis treated with first line drugs. However, MDR-tuberculo…”
HIV Infection and Multidrug‐Resistant Tuberculosis—The Perfect Storm
Wells, C. D., Cegielski, J. P., Nelson, L. J., Laserson, K. F., Holtz, T. H., Finlay, A., Castro, K. G., & Weyer, K. (2007) · The Journal of Infectious Diseases · doi:10.1086/518665 · Cited by 483 · cited 4×
“As regards CF, the review of Payne and Bellamy [143] provided no information on the prognosis of HIV positive MDR-tuberculosis patients.”
BackgroundInfluentialTreatment of Tuberculosis in Patients with Advanced Human Immunodeficiency Virus Infection
Small, P. M., Schecter, G. F., Goodman, P. C., Sande, M. A., Chaisson, R. E., & Hopewell, P. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101313240503 · Cited by 477 · cited 1×
“tuberculosis, of 16 months [145].”
The White Plague: Tuberculosis, Man and Society
(1954) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1954.tb85837.x · Cited by 388
Recurrence in tuberculosis: relapse or reinfection?
Lambert, M.-L., Hasker, E., Deun, A. V., Roberfroid, D., Boelaert, M., & Van der Stuyft, P. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00607-8 · Cited by 225 · cited 1×
“Moreover, of the two possible end points, cure is hard to measure, as relapses are common [140] and establishing cure in untreated tuberculosis patients requires extensive medical investigations.”
Background
Research works printed but not linked: 25
- JA Rutledge, 1919, The ultimate results in 1654 cases of tuberculosis treated at the modern Woodmen of America sanatorium., Am Rev Tuberc, 2, 755
- E Loewenstein, 1931, Die Zuchtung der Tuberkelbazillen aus dem stroemenden Blute., Zentralbl Bakteriol Parasitenkd Infektionskr Hyg, 1, 127
- KA Jensen, 1932, Reinzuchtung und Typenbestimmung von Tuberkelbazillenstammen., Zentralb Bakteriol Parasitenkd Infektionskr Hyg Abt, 1, 222
- GH Hamel, 1928, Jahresversammlung des Deutschen Zentral-komitees zur Bekämpfung der Tuberkulose. Erster Verhandlungstag. (discussions during annual meeting of the German Tuberculosis Control Committee)., Zeitschr Tuberk, 51, 497
- B Meidell, 1931, Die wahrscheinliche Lebensdauer und die Sterblichkeitsmessung., Skandinavisk aktuarietidskrift, 14, 217
- Anonymous, 1936, The expectation of life of the tuberculous., Tubercle, 17, 171
- F Oldenburg, 1931, Gedanken über das Schicksal offentuberkulöser Eisenbahner auf Grund statistischer Erhebungen., Zeitschr Tuberk, 61, 334
- S Phillips, 1964, Relapse in treated cases of pulmonary tuberculosis. II. Six-year follow-up of 109 patients discharged from the hospital with medical approval, 1955-1956., Am Rev Respir Dis, 90, 61
- W May, 1928, Welche Konsequenzen ergeben sich aus der Dauerstatistik der Heilverfahren bei Offentuberkulösen?, Zeitschr Tuberk, 51, 177
- H Ruge, 1909, Dauererfolge nach 10 Jahren bei Lungetuberkulose im Hochgebirge., Zeitsch Tuberk, 15, 146
- E Saegler, 1934, Beitrag zur Frage der Beziehungen zwischen Tuberkulose und Lebensalter., Zeitschr Tuberk, 71, 285
- E Stadler, 1903, Der Einfluss der Lungetuberkulose of Lebensdauer und Erwerbsfähigkeit und der Werth der Volksheilstättenbehandlung., Deutsch Arch Klin Med, 95, 412
- MG Stephens, 1941, Follow-up of 1041 tuberculous patients., Am Rev Tuberc, 44, 451
- PF Holst, 1906, Untersuchungen über die Lebensdauer der Schwindsüchtigen in Norwegen., Deutsch Arch Klin Med, 88, 325
- H Braeuning, 1920, Tuberkulöse Erkrankungen bei Schwestern infolge von Ansteckung im Dienst und ihre Verhütung., Zeitschr Tuberk, 33, 129
- AD De Besche, 1925, Dødeligheten av Lungentuberkulose i Oslo blandt til Byen indflyttede og der fødte Individer., Norsk Magazin for Laegevidenskaben, 86, 1229
- CRNF Van Joost, 1935, Opmerkingen naar aanleiding van een 200 tal met kunstmatige pneumothorax- en een 50 tal met middenrifsverlamming (phrenicusexairesis) behandelde gevallen van longtuberculose., Geneeskund Tijdschr v Ned Indië, 75, 1223
- B Van Vliet, 1963, Analyse van de sterfte aan longtuberculose te Amsterdam in de jaren 1960 en 1961., Ned Tijdschr Geneesk, 107, 2180
- SP Pamra, 1973, Changes in prevalence and incidence of pulmonary tuberculosis in Delhi in recent years., Ind J Tuberc, 20, 57
- CMF Sinding-Larsen, 1937, On the collapse treatment of pulmonary tuberculosis. A clinical adaption and follow-up examination of the material from Vejlefjord Sanatorium, 1906-1932., Acta Med Scand, 91, 39
- S Magnusson, 1938, Über den Verlauf und die Letalität der Tuberkulose in den verschiedenen Altersperioden., Acta Tuberc Scand, 12, 201
- W Münchbach, 1933, Das Schicksal des lungentuberkulösen Erwachsenen. Ergibnisse der Heilstattenbehandlung von annähernd 10000 Männern und Frauen., Tuberkulose-Bibliothek, 49, 64
- H Braeuning, 1936, Prognose der offenen Tuberkulose, Technik der Prognose-stellung und Rentabilität des Heilverfahrens., Zeitschr Tuberk, 75, 305
- H Braeuning, 1933, Die Prognose der offenen Lungentuberkulose., Tuberkulose-Bibliothek, 52, 40
- H Braeuning, 1930, Über die Letalität, Morbidität und Infektionsdauer der offenen Lungentuberkulose., Zeitschr Tuberk, 59, 109
Cited by
Items 101–200 of 630
Dawit, Z., Abebe, S., Dessu, S., Gesese, M. M., Sahile, S., & Ajema, D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253449 · Cited by 39
“Relatively, a small proportion of people infected with Mycobacterium tuberculosis will develop TB disease but the probability of developing TB is much higher among people infected with HIV [8].”
BackgroundViegelmann, C., Parker, J., Ooi, T., Clements, C. J., Abbott, G. M., Young, L., Kennedy, J., Dobson, A. D. W., & Edrada‐Ebel, R. (2014) · Marine Drugs · doi:10.3390/md12052937 · Cited by 39
“The mortality rate is higher for HIV positive patients with untreated TB as the average survival rate becomes less than 6 months [5].”
BackgroundKim, J., Keshavjee, S. A., & Atun, R. A. (2019) · Journal of Global Health · doi:10.7189/jogh.09.010423 · Cited by 43
Malmborg, R., Mann, G. H., & Squire, S. B. (2011) · International Journal for Equity in Health · doi:10.1186/1475-9276-10-49 · Cited by 39
Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis
Gomez, G. B., Dowdy, D. W., Bastos, M. L., Zwerling, A. A., Sweeney, S., Foster, N., Trajman, A., Islam, M. A., Kapiga, S., Sinanovic, E., et al. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-2064-3 · Cited by 45
It Is Time to Focus on Asymptomatic Tuberculosis
Wong, E. B. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1827 · Cited by 39
“Indeed, literature from the preantibiotic era demonstrates that self-cure was common even in patients with full-blown TB [8].”
BackgroundSkeletal Lesions in Human Tuberculosis May Sometimes Heal: An Aid to Palaeopathological Diagnoses
Holloway‐Kew, K. L., Link, K., Rühli, F. J., & Henneberg, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062798 · Cited by 45
Tuberculosis is a Fatal Disease among Some Developing Countries of the WorldPreprint
Mohajan, H. K. (2015) · RePEc: Research Papers in Economics · doi:10.12691/ajidm-3-1-4 · Cited by 38
Ragonnet, R. R., Flegg, J. A., Brilleman, S. L., Tiemersma, E. W., Melsew, Y. A., McBryde, E. S., & Trauer, J. M. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa602 · Cited by 37
Self-citationRibeiro, F. M., & Goldenberg, T. (2015) · Lupus · doi:10.1177/0961203314559634 · Cited by 40
Success of active tuberculosis case detection among high-risk groups in urban slums in Pakistan
Fatima, R., Qadeer, E., Enarson, D. A., Creswell, J., Stevens, R. H., Hinderaker, S. G., & Haq, M. U. (2014) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.14.0001 · Cited by 42
Human Tuberculosis I. Epidemiology, Diagnosis and Pathogenetic Mechanisms
Sgaragli, G., & Frosini, M. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160607222854 · Cited by 39
“it Among sputum-smear-positive cases of pulmonary tuberculosis in HIV-negative patients, the estimated 10-year case fatality rate is 70% [9].”
BackgroundScalacci, N., Brown, A. K., Pavan, F. R., Ribeiro, C. M., Manetti, F., Bhakta, S., Maitra, A., Smith, D., Petricci, E., & Castagnolo, D. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.042 · Cited by 36
“8% of global TB patients are co-infected with HIV and can be credited as one of the most common causes of death among AIDS patients [2,3].”
Does tuberculosis screening improve individual outcomes? A systematic review
Telisinghe, L., Rupérez, M., Amofa-Sekyi, M., Mwenge, L., Mainga, T., Kumar, R., Hassan, M., Chaisson, L. H., Naufal, F., Shapiro, A. E., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101127 · Cited by 41
“If untreated, TB is associated with high mortality and morbidity [6].”
BackgroundSun, A. Y., Pai, M., Salje, H., Satyanarayana, S., Deo, S., & Dowdy, D. W. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kwt210 · Cited by 35
Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis
Kübler, A., Larsson, C., Luna, B. M., Andrade, B. B., Amaral, E. P., Urbanowski, M. E., Orandle, M. S., Bock, K. W., Ammerman, N. C., Cheung, L. S., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv458 · Cited by 35
“Tuberculosis is a common, debilitating infectious disease that, if left untreated, has a fatality rate of >50% [1].”
BackgroundTHE ENGINE AND THE REAPER: INDUSTRIALIZATION AND MORTALITY IN LATE NINETEENTH CENTURY JAPAN
Tang, J. P. (2017) · Journal of Health Economics · doi:10.1016/j.jhealeco.2017.09.004 · Cited by 38
Nsengiyumva, N. P., Hussain, H., Oxlade, O., Majidulla, A., Nazish, A., Khan, A. J., Menzies, D., Ahmad Khan, F., & Schwartzman, K. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab567 · Cited by 34
“Smear-positive patients 23 (18–29) [13, 14]”
Senkoro, M., Hinderaker, S. G., Mfinanga, S., Range, N. S., Kamara, D., Egwaga, S., & van Leth, F. (2015) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.14.0499 · Cited by 34
Weerasuriya, C. K., Harris, R. C., McQuaid, C. F., Bozzani, F. M., Ruan, Y., Li, R., Li, T., Rade, K., Rao, R., Ginsberg, A. M., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-01932-7 · Cited by 39
Risk factors associated with unsuccessful tuberculosis treatment outcomes in Hunan Province, China
Gilmour, B., Xu, Z., Bai, L., Alene, K. A., & Clements, A. (2022) · Tropical Medicine & International Health · doi:10.1111/tmi.13720 · Cited by 34
“Tuberculosis can be cured, but if left untreated the mortality rate is high, with 10year case fatality rates ranging between 54 and 86% in human immunodeficiency virus (HIV) negative patients [4].”
BackgroundThe role of mobility and health disparities on the transmission dynamics of Tuberculosis
Moreno, V., Espinoza, B., Barley, K., Paredes, M., Bichara, D. M., Mubayi, A., & Castillo‐Chávez, C. (2017) · Theoretical Biology and Medical Modelling · doi:10.1186/s12976-017-0049-6 · Cited by 34
Lu, X., Smare, C., Kambili, C., Khoury, A. C. E., & Wolfson, L. J. (2017) · BMC Health Services Research · doi:10.1186/s12913-016-1931-3 · Cited by 34
Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape
Phillips, P. P. J., Mitnick, C. D., Neaton, J. D., Nahid, P., Lienhardt, C., & Nunn, A. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002767 · Cited by 33
“For example, a somewhat conservative estimate of the success rate of standard therapy in DS-TB is around 85% [42], which, compared to the estimated 30% survival from untreated TB [43], gives an estimate of an absolute treatment effect of 55%.”
ResultGayoso, R., Dalcolmo, M. P., Braga, J. U., & Barreira, D. (2018) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2018.07.002 · Cited by 32
Guo, Z., Xiao, D., Wang, X., Wang, Y., & Yan, T. (2019) · BMC Public Health · doi:10.1186/s12889-019-6544-4 · Cited by 34
Mariotti, S., Pardini, M., Gagliardi, M. C., Teloni, R., Giannoni, F., Fraziano, M., Lozupone, F., Meschini, S., & Nisini, R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202900 · Cited by 36
Transmission of multidrug-resistant tuberculosis in the USA: a cross-sectional study
Moonan, P. K., Teeter, L. D., Salcedo, K. L., Ghosh, S., Ahuja, S. D., Flood, J., & Graviss, E. A. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70128-2 · Cited by 32
Kendall, E. A., Fojo, A. T., & Dowdy, D. W. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30423-4 · Cited by 31
Vekemans, J., Brennan, M. J., Hatherill, M., Schrager, L. K., Fritzell, B., Rutkowski, K. T., Vos, B. D., Zignol, M., Thiry, G., Ginsberg, A. M., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.10.072 · Cited by 31
Clark, R. A., Weerasuriya, C. K., Portnoy, A., Mukandavire, C., Quaife, M., Bakker, R., Scarponi, D., Harris, R. C., Rade, K., Mattoo, S. K., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02992-7 · Cited by 34
“1, 2 [5, 18, 21–37].”
Population-Level Impact of Active Tuberculosis Case Finding in an Asian Megacity
Dowdy, D. W., Lotia‐Farrukh, I., Azman, A. S., Creswell, J., Sahu, S., & Khan, A. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077517 · Cited by 31
“1 Spontaneous-cure rate from SN and EP, yearly [8] ρLf 0.”
BackgroundInfluentialDowdy, D. W., Davis, J. L., den Boon, S., Walter, N. D., Katamba, A., & Cattamanchi, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070485 · Cited by 34
“115 [34]”
Deffur, A., Mulder, N., & Wilkinson, R. J. (2013) · Pathogens and Disease · doi:10.1111/2049-632x.12060 · Cited by 31
Estimating the Burden of Tuberculosis in India: A Modelling Study
Mandal, S., Rao, R., & Joshi, R. P. (2023) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_160_23 · Cited by 30
Jakab, Z., Acosta, C. D., Kluge, H. H. P., & Dara, M. (2015) · Tuberculosis · doi:10.1016/j.tube.2015.02.027 · Cited by 30
“The number of M/ XDR-TB cases that cure spontaneously was assumed to be 5% and the case fatality rate without intervention was assumed to be 30% [12].”
BackgroundTuberculosis Prevention in South Africa
Knight, G. M., Dodd, P. J., Grant, A. D., Fielding, K., Churchyard, G., & White, R. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122514 · Cited by 29
“Active TB without treatment results in death (70% for smear-positive disease; 30% for smear-negative disease) or else self-cure over a timescale of 3 years based on [12].”
BackgroundFofana, M. O., Shrestha, S., Knight, G. M., Cohen, T., White, R. G., Cobelens, F. G. J., & Dowdy, D. W. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00498-16 · Cited by 28
Tafess, K., Beyen, T. K., Abera, A., Tasew, G., Mekit, S., Sisay, S., Tadesse, L., & Siu, G. G. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00038 · Cited by 28
Borad, M. A., Jethava, D. J., Bhoi, M. N., Patel, C., Pandya, H. A., & Patel, H. D. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.128881 · Cited by 28
Zawahir, S., Le, H., Nguyen, T. A., Beardsley, J., Duc, A. D., Bernays, S., Viney, K. A., Cao, T. H., McKinn, S., Tran, H. H., et al. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2021-006475 · Cited by 28
Sachdeva, K. S., Raizada, N., Gupta, R. S., Nair, S. A., Denkinger, C. M., Paramasivan, C. N., Kulsange, S., Thakur, R., Dewan, P. K., Boehme, C. C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131438 · Cited by 28
mTORC2/Akt activation in adipocytes is required for adipose tissue inflammation in tuberculosis
Martínez, N., Cheng, C. Y., Ketheesan, N., Cullen, A. M., Tang, Y., Lum, J., West, K., Poidinger, M., Guertin, D. A., Singhal, A., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.052 · Cited by 28
“This is an open access article under state in ~90% of infected individuals and when active TB develops, the average duration of untreated disease prior to death or nonsterilizing recovery is estimated to be 2–3 years [3].”
BackgroundModelling the impact of effective private provider engagement on tuberculosis control in urban India
Arinaminpathy, N., Deo, S., Singh, S., Khaparde, S., Rao, R., Vadera, B., Kulshrestha, N., Gupta, D., Rade, K., Nair, S. A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39799-7 · Cited by 27
Cardona, P.-J., Català, M., & Prats, C. (2020) · Scientific Reports · doi:10.1038/s41598-019-56769-1 · Cited by 34
Sparacello, V., Roberts, C. A., Canci, A., Moggi‐Cecchi, J., & Marchi, D. (2016) · International Journal of Paleopathology · doi:10.1016/j.ijpp.2016.08.003 · Cited by 33
“Cross-sectional indices and shape Patterns in cross-sectional indices can be informative about subsistence practices (Trinkaus and Ruff, 1999).”
BackgroundAn agent-based simulation of a Tuberculosis epidemic: Understanding the timing of transmission
Kasaie, P., Dowdy, D. W., & Kelton, W. D. (2013) · Winter Simulation Conference · doi:10.1109/wsc.2013.6721599 · Cited by 27
Cost-effectiveness of novel first-line treatment regimens for tuberculosis
Owens, J. P., Fofana, M. O., & Dowdy, D. W. (2013) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0776 · Cited by 26
Wirth, D., Dass, R., & Hettle, R. (2017) · BMC Health Services Research · doi:10.1186/s12913-017-2118-2 · Cited by 26
Prevalence of Tuberculosis in HIV-positive Prisoners: A Systematic Review and Meta-analysis
Joulaei, H., Fararouei, M., Ghorbani, M., Dianatinasab, M., Zarei, N., Rezaeian, S., & Greenwald, Z. R. (2018) · Aids Reviews · doi:10.24875/aidsrev.m18000023 · Cited by 26
Challenges in the clinical assessment of novel tuberculosis drugs
Dooley, K. E., Phillips, P. P. J., Nahid, P., & Höelscher, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.014 · Cited by 26
“Current treatment for MDR-TB requires ≥20 months of multidrug therapy, including ≥8 months of an injectable agent [7], and yet is successful in only 48% of patients [2], not very different from the cure rates in the pre-antibiotic era-30% for sputum smear positive and 80% for sputum smear negative, culture positive TB…”
BackgroundRevolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon
Kufa, M., Finger, V., Kovar, O., Soukup, O., Torruellas, C., Roh, J., & Korábečný, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.01.023 · Cited by 27
“If inadequately treated, the active form of TB is often fatal, reaching a mortality rate up to 50% 4 .”
InfluentialEisentraut, L., Mai, C., Hosch, J., Benecke, A., Penava, P., & Buettner, R. (2025) · IEEE Access · doi:10.1109/access.2025.3544923 · Cited by 30
“Given the severe consequences of untreated TB [3], missed diagnoses can result in significant adverse outcomes for patients, including prolonged illness or even death [1].”
Ricks, S., Denkinger, C. M., Schumacher, S. G., Hallett, T. B., & Arinaminpathy, N. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003466 · Cited by 30
Effects of Ascent to High Altitude on Human Antimycobacterial Immunity
Eisen, S., Pealing, L. M., Aldridge, R. W., Siedner, M. J., Necochea, A., Leybell, I., Valencia, T. R., Herrera, B., Wiles, S., Friedland, J. S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074220 · Cited by 25
Elbehiry, A., Marzouk, E., Edrees, H. M., AlShaqi, R., Ellethy, A. T., Alzaben, F. A., Anagreyyah, S. A., Algarni, A., Almuhaydili, K., AlOtaibi, I. A. B., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1596579 · Cited by 35
Korenromp, E. L., Glaziou, P., Fitzpatrick, C., Floyd, K., Hosseini, M., Raviglione, M. C., Atun, R. A., & Williams, B. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038816 · Cited by 23
“The global average case fatality rates were derived from published studies and systematic reviews identified through a PubMed search, up to December 2011 [1,9,10,14,15,16], and treatment outcome data reported by NTPs to WHO.”
BackgroundMethodSelf-citationSsengooba, W., Respeito, D., Mambuque, E., Blanco, S., Bulo, H., Mandomando, I., de Jong, B. C., Cobelens, F. G. J., & García‐Basteiro, A. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162833 · Cited by 23
Preventing the White Death: Tuberculosis Dispensaries
Egedesø, P. J., Hansen, C. W., & Jensen, P. S. (2020) · The Economic Journal · doi:10.1093/ej/ueaa014 · Cited by 30
Filho, J. B. D. O. E. S., Sanchez, M. N., Seixas, J. M., Maidantchik, C., Galliez, R. M., Moreira, A. D. S. R., da Costa, P. A., Oliveira, M. M., Harries, A. D., & Kritski, A. L. (2018) · Tuberculosis · doi:10.1016/j.tube.2018.05.012 · Cited by 22
Ragonnet, R. R., Williams, B. M., Largen, A., Nasa, J., Jack, T., Langinlur, M. K., Ko, E., Rahevar, K., Islam, T., Denholm, J. T., et al. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac045 · Cited by 23
Self-citationEngström, A. (2015) · Scandinavian Journal of Infectious Diseases · doi:10.3109/23744235.2015.1061205 · Cited by 25
Therapy duration and long-term outcomes in extra-pulmonary tuberculosis
Pusch, T., Pasipanodya, J. G., Hall, R. G., & Gumbo, T. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-115 · Cited by 23
“pulmonary tuberculosis that is smear negative but culture positive is 12-15%, while that for sputum positive is 4270% [37].”
BackgroundMathematical Modeling of “Chronic” Infectious Diseases: Unpacking the Black Box
Fojo, A. T., Kendall, E. A., Kasaie, P., Shrestha, S., Louis, T. A., & Dowdy, D. W. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx172 · Cited by 22
Agnarson, A. M., Williams, A., Kambili, C., Mattson, G., & Metz, L. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1742109 · Cited by 23
“Two scenarios were explored, whereby the rate of hospitalization of MDR/XDR-TB patients at diagnosis and treatment initiation increased from 10% (base case) to 20.6 and 50%, to reflect reports of hospitalization from Schnippel et al. (2018) and the WHO (2018), respectively [42].”
BackgroundResultInfluentialPattern of InhA and KatG mutations in isoniazid monoresistant Mycobacterium tuberculosis isolates
Gupta, N., Charan, A., Dixit, R., Arora, P., Patni, T., Antony, K., & Singh, M. (2020) · Lung India · doi:10.4103/lungindia.lungindia_204_19 · Cited by 23
“Mutations in inhA, on the other hand, may respond to high doses of INH.[11]”
BackgroundInfluentialDefining Outcomes of Tuberculosis (Treatment): From the Past to the Future
Günther, G., Heyckendorf, J., Zellweger, J. P., Reimann, M., Claassens, M. M., Chesov, D., & van Leth, F. (2021) · Respiration · doi:10.1159/000516392 · Cited by 22
Modelling challenges in context: Lessons from malaria, HIV, and tuberculosis
Childs, L. M., Abuelezam, N. N., Dye, C., Gupta, S., Murray, M. B., Williams, B. G., & Buckee, C. O. (2015) · Epidemics · doi:10.1016/j.epidem.2015.02.002 · Cited by 26
“The lack of data on the distribution of times between becoming infectious to self-cure, disease or diagnosis, with indirect estimates suggesting that this period can range from a few months to several years (35), makes realistic incorporation of the initiation of active disease into models difficult (Article 22 (36) C…”
BackgroundSelf-citationModular programming for tuberculosis control, the “AuTuMN” platform
Trauer, J. M., Ragonnet, R. R., Doan, T. N., & McBryde, E. S. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2648-6 · Cited by 21
“…efficacy [13], waning risk of progression to active disease with time from infection [14, 15], a three year average duration of active disease [16], distinguishing the process of detection from that of determining the drug resistance profile [9], amplification of drug resistance with default…”
BackgroundLi, J., Yip, B. H. K., Leung, C., Chung, W., Kwok, K. O., Chan, E. Y. Y., Yeoh, E., & Chung, P.-H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0189531 · Cited by 21
Elsafi, S. S. M., Nour, B. Y. M., Abakar, A. D., Omer, I. H., & Almugadam, B. S. (2020) · AIMS Microbiology · doi:10.3934/microbiol.2020004 · Cited by 21
“Tuberculosis (TB) is a major public health problem and cause of mortality globally [1].”
BackgroundAdolescents and young adults: a neglected population group for tuberculosis surveillance
García‐Basteiro, A. L., Schaaf, H. S., Diel, R., & Migliori, G. B. (2018) · European Respiratory Journal · doi:10.1183/13993003.00176-2018 · Cited by 21
Naidoo, K., Moodley, M. C., Hassan-Moosa, R., Dookie, N., Yende‐Zuma, N., Perumal, R., Dawood, H., Mvelase, N. R., Mathema, B., & Karim, S. S. A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac185 · Cited by 20
“Previous studies also postulated that TB cycles through incipient and subclinical TB phases [25].”
Bovine Tuberculosis (TB): A Review Of Cattle-To-Cattle Transmission, Risk Factors And Susceptibility
Skuce, R., Allen, A. R., & McDowell, S. W. J. (2011) · Cited by 30
Current Medical Management of Pulmonary Tuberculosis
Belknap, R. (2018) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2018.09.004 · Cited by 20
“10-year mortality of 70%.(5) Late diagnoses also result inpermanent lungdamage formanypatients.”
BackgroundTrentalange, A., Borgogno, E., Motta, I., Antonucci, M., Pirriatore, V., Costa, C., Rossi, G., Barco, A., Nicolò, A. D., Piccioni, P., et al. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106297 · Cited by 19
SEIRS model for TB transmission dynamics incorporating the environment and optimal control
Ochieng, F. O. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10710-2 · Cited by 19
“The incubation period of tuberculosis (TB) can vary widely, but is generally estimated to be between 2 and 10 weeks [19].”
Romanowski, K., Campbell, J. R., Oxlade, O., Fregonese, F., Menzies, D., & Johnston, J. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211355 · Cited by 19
An Elucidation of Neutrophil Functions againstMycobacterium tuberculosisInfection
Morris, D., Nguyen, T., Kim, J., Kassissa, C., Khurasany, M., Luong, J. C., Kasko, S., Pandya, S., Chu, M., Chi, P.-T., et al. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/959650 · Cited by 23
“Left untreated TB is known to have a 70% mortality rate [2].”
BackgroundCost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
Codecasa, L. R., Toumi, M., D’Ausilio, A., Aiello, A., Damele, F., Termini, R., Uglietti, A., Hettle, R., Graziano, G., & Lorenzo, S. D. (2017) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2017.1283105 · Cited by 18
Shaweno, D., Trauer, J. M., Denholm, J. T., & McBryde, E. S. (2018) · Royal Society Open Science · doi:10.1098/rsos.180887 · Cited by 18
Strategic Planning for Tuberculosis Control in the Republic of Fiji
Ragonnet, R. R., Underwood, F., Doan, T. N., Rafai, E., Trauer, J. M., & McBryde, E. S. (2019) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed4020071 · Cited by 17
“An untreated episode of active TB was assumed to last for around three years (although uncertainty was included around this parameter), with a greater case fatality rate for smear-positive active TB than for smear-negative and extrapulmonary disease (Supplement page 17) [10].”
BackgroundMVA85A vaccine to enhance BCG for preventing tuberculosis
Kashangura, R., Jullien, S., Garner, P., & Johnson, S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012915.pub2 · Cited by 22
“Tiemersma 2011 Tiemersma EW, van der Werf MJ, BorgdorE MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review.”
BackgroundAvilov, K. K., Romanyukha, A. A., Borisov, S. E., Belilovsky, E. M., Nechaeva, O. B., & Karkach, A. S. (2015) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.14.0317 · Cited by 17
Park, H., Ku, H., Sohn, H.-S., Seo, H., Lee, H. Y., Lim, K. H., & Kwon, J. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.01.023 · Cited by 17
Venous thrombotic events in patients admitted to a tuberculosis centre
Howard, J. B., Bierman, W. F. W., Meijer, K., van der Werf, T. S., & Tichelaar, Y. I. G. V. (2016) · QJM · doi:10.1093/qjmed/hcw152 · Cited by 17
Candidate transmission survival genome of Mycobacterium tuberculosis
Mishra, S., Singh, P. R., Hu, X., Quezada, L. A. L., Jinich, A., Jahn, R., Geurts, L., Shen, N., DeJesus, M. A., Hartman, T. E., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2425981122 · Cited by 17
Zheng, N., Whalen, C. C., & Handel, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105721 · Cited by 16
“25 per year return from active TB stage to latency [81]”
BackgroundPopulation-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis
Fofana, M. O., Knight, G. M., Gomez, G. B., White, R. G., & Dowdy, D. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096389 · Cited by 16
“Active TB mortality, per year 20% 10–40% [19]”
BackgroundAzwar, G. A., Noviana, D. I., & Hendriyono, F. (2017) · Berkala Kedokteran · doi:10.20527/jbk.v13i1.3436 · Cited by 16
Lui-Filho, J. F., Pedro, A. O., Baccaro, L. F., & Costa‐Paiva, L. (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001022 · Cited by 16
Mansukoski, L., & Sparacello, V. (2018) · International Journal of Paleopathology · doi:10.1016/j.ijpp.2017.12.005 · Cited by 19
Alghamdi, S. A., Rehman, S. U., Shesha, N. T., Faidah, H. S., Khurram, M., & Rehman, S. U. (2020) · Molecules · doi:10.3390/molecules25235685 · Cited by 17
“In 80–90% of the cases, these aerobic bacilli enter the lungs, while other extrapulmonary organs, primarily lymph nodes, bones, joints, and the genitourinary system are affected as well [2].”
BackgroundSegala, F. V., Papagni, R., Cotugno, S., Vita, E. D., Susini, M. C., Filippi, V., Tulone, O., Facci, E., Lattanzio, R., Marotta, C., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1117709 · Cited by 15
Koyuncu, D., Tavolara, T. E., Gatti, D. M., Gower, A. C., Ginese, M. L., Kramnik, I., Yener, B., Sajjad, U., Niazi, M. K. K., Gürcan, M. N., et al. (2024) · Infection and Immunity · doi:10.1128/iai.00263-23 · Cited by 16
Wolde, H. F., Clements, A., & Alene, K. A. (2025) · Journal of Global Health · doi:10.7189/jogh.15.04004 · Cited by 18
“To minimise mortality caused by TB, it is essential that everyone who develops the disease can quickly access diagnosis and treatment, as 70% of untreated smear-positive TB cases will die within 10 years of their diagnosis [ 51 ].”
Scenario Analysis for Programmatic Tuberculosis Control in Western Province, Papua New Guinea
Trauer, J. M., Denholm, J. T., Waseem, S., Ragonnet, R. R., & McBryde, E. S. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kwv323 · Cited by 15
Snoddy, A. M. E., Buckley, H. R., King, C. L., Kinaston, R. L., Nowell, G. M., Gröcke, D. R., Duncan, W., & Petchey, P. (2020) · Bioarchaeology International · doi:10.5744/bi.2019.1014 · Cited by 17
Chronic Pulmonary Aspergillosis as a Considerable Complication in Post-Tuberculosis Lung Disease
Neuböck, M. J., Günther, G., Barac, A. M., Davidsen, J. R., Laursen, C. B., Agarwal, R., Sehgal, I. S., Lange, C. G., Salzer, H. J. F., & CPAnet, F. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1776913 · Cited by 16
A user-friendly, open-source tool to project impact and cost of diagnostic tests for tuberculosis
Dowdy, D. W., Andrews, J. R., Dodd, P. J., & Gilman, R. H. (2014) · eLife · doi:10.7554/elife.02565 · Cited by 14
“…from TB HIV-negative, smear-positive/highly infectious 0.23/year (Tiemersma et al., 2011) HIV-negative, smear-negative/less infectious 0.07/year (Tiemersma et al., 2011) HIV-infected 1.0/year (Corbett et al., 2003; Corbett et al., 2007; Wood et al., 2007) Rate of spontaneous TB resolution…”
BackgroundInfluential
Metadata
- Authors
- Tiemersma, E. W., van der Werf, M. J., Borgdorff, M. W., Williams, B. G., & Nagelkerke, N. J. D.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- GGD Amsterdam (NL)
- Stellenbosch University (ZA)
- United Arab Emirates University (AE)
- Corresponding author
- Tiemersma, Edine W.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-04-04
- Volume
- 6
- Issue
- 4
- Pages
- e17601
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3070694
- OpenAlex
- W2138041013
- Cited by
- 583
- References
- 136
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 46 · 2023: 48 · 2022: 40 · 2021: 36 · 2020: 38 · 2019: 39 · 2018: 43 · 2017: 42 · 2016: 35 · 2015: 43 · 2014: 39 · 2013: 31 · 2012: 10
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- UvA-DARE (University of Amsterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- SUNScholar (Stellenbosch University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV, TB, and STIs Epidemiology
- Keywords
- case fatality, disease duration, HIV-negative patients, smear-positive tuberculosis, smear-negative tuberculosis, culture-positive tuberculosis, tuberculosis prognosis
- MeSH terms
- Humans, Time Factors, Tuberculosis, Pulmonary, Survival Analysis, HIV Seronegativity, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.